Background: Lower-grade gliomas (LGG) are associated with inevitable progression and poor outcomes. Kinesin family member 11 (KIF11), a motor protein driving mitotic spindle formation, is overexpressed in various cancers, yet its comprehensive prognostic and immunological significance in LGG has not been systematically evaluated. Methods: Transcriptomic data from 522 LGG samples (TCGA) and 1,152 normal brain samples (GTEx) were analyzed. Differential expression, receiver operating characteristic (ROC) curve, Kaplan-Meier and Cox regression, gene set enrichment analysis (GSEA), and immune infiltration profiling were performed. Results: KIF11 was significantly upregulated in LGG (area under the ROC curve [AUROC]=0.984). High expression correlated with tumor status but not age or sex. Elevated KIF11 was independently associated with worse overall survival (OS) (HR=1.87, p<0.05), disease-specific survival (hazard ratio [HR]=1.55, p<0.05), and progression-free interval (HR=2.02, p<0.05). GSEA identified enrichment of mitotic chromosome segregation and cell cycle pathways. A significant positive correlation was observed between KIF11 expression and type 2 helper T cell infiltration (r=0.624, p<0.001). Conclusions: KIF11 is identified as a prognostic biomarker in LGG, with elevated expression linked to adverse outcomes, cell cycle dysregulation, and potential modulation of the immune microenvironment. These findings may inform risk stratification and therapeutic development.
References
[1] Khan, A. A., Waheed, A. A., Ahmed, A. A., Hafiz, A., Zaki, A., Gilani, A., Urooj, F., Bajwa, M. H., Enam, S. A. (2024) Consensus guidelines for the management of adult low-grade gliomas for low and middle-income countries. The Journal of the Pakistan Medical Association, 74(3 (Supple-3)), S93-S99.
[2] An, Y., Wang, Q., Zhang, L., Sun, F., Zhang, G., Dong, H., Li, Y., Peng, Y., Li, H., Zhu, W, Ji, S., Wang, Y., Guo, X. (2020) OSlgg: an online prognostic biomarker analysis tool for low-grade glioma. Frontiers in Oncology, 10, 1097.
[3] Dono, A., Ballester, L. Y., Primdahl, D., Esquenazi, Y., Bhatia, A. (2021) IDH-mutant low-grade glioma: advances in molecular diagnosis, management, and future directions. Current Oncology Reports, 23(2), 20.
[4] Chen, D., Yao, J., Hu, B., Kuang, L., Xu, B., Liu, H., Dou, C., Wang, G., Guo, M. (2022) New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis. Chinese Neurosurgical Journal, 8(03), 169-177.
[5] Zhang, C., Wang, L., Liu, H., Deng, G., Xu, P., Tan, Y., Xu, Y., Liu, B., Chen, Q., Tian, D. (2021) ADPRH is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma. Journal of Cancer, 12(10), 2912.
[6] de Blank, P., Fouladi, M., Huse, J. T. (2020) Molecular markers and targeted therapy in pediatric low-grade glioma. Journal of Neuro-Oncology, 150(1), 5-15.
[7] Gao, W., Lu, J., Yang, Z., Li, E., Cao, Y., Xie, L. (2024) Mitotic functions and characters of KIF11 in cancers. Biomolecules, 14(4), 386.
[8] Guo, X., Zhou, L., Wu, Y., Li, J. (2022) KIF11 as a potential pan‐cancer immunological biomarker encompassing the disease staging, prognoses, tumor microenvironment, and therapeutic responses. Oxidative Medicine and Cellular Longevity, 2022(1), 2764940.
[9] Cheng, X., Zhao, H., Li, Z., Yan, L., Min, Q., Wu, Q., Zhan, Q. (2025) Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma. Journal of Translational Medicine, 23(1), 197.
[10] Hu, Z. D., Jiang, Y., Sun, H. M., Wang, J. W., Zhai, L. L., Yin, Z. Q., Yan, J. (2021) KIF11 promotes proliferation of hepatocellular carcinoma among patients with liver cancers. BioMed Research International, 2021(1), 2676745.
[11] Liu, B., Zhang, G., Cui, S., Du, G. (2022) Upregulation of KIF11 in TP53 mutant glioma promotes tumor stemness and drug resistance. Cellular and Molecular Neurobiology, 42(5), 1477-1485.
[12] Venere, M., Horbinski, C., Crish, J. F., Jin, X., Vasanji, A., Major, J., Burrows, A., Chang, C., Prokop, J., Wu, Q., Sims, P. A., Canoll, P., Summers, W. K., Rosenfeld, S. S., Rich, J. N. (2015) The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma. Science Translational Medicine, 7(304), 304ra143.
[13] Özbek, M., Toy, H. I., Oktay, Y., Karakülah, G., Suner, A., Pavlopoulou, A. (2023) An in silico approach to the identification of diagnostic and prognostic markers in low-grade gliomas. PeerJ, 11, e15096.
[14] Wu, S., Lv, X., Li, Y., Gao, X., Ma, Z., Fu, X., Li, Y. (2022) Integrated machine learning and single‐sample gene set enrichment analysis identifies a TGF‐Beta signaling pathway derived score in headneck squamous cell carcinoma. Journal of Oncology, 2022(1), 3140263.
[15] Ru, B., Wong, C. N., Tong, Y., Zhong, J. Y., Zhong, S. S. W., Wu, W. C., Chu, K. C., Wong, C. Y., Lau, C. Y., Chen, I., Chan, N. W., Zhang, J. (2019) TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics, 35(20), 4200-4202.
[16] Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., Omberg, L., Wolf, D. M., Shriver, C. D., Thorsson, V., Hu, H. (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell, 173(2), 400-416.
[17] Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J. C., Müller, M. (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics, 12(1), 77.
[18] Jungwirth, G., Yu, T., Moustafa, M., Rapp, C., Warta, R., Jungk, C., Sahm, F., Dettling, S., Zweckberger, K., Lamszus, K., Senft, C., Loehr, M., Keßler, A. F., Ketter, R., Westphal, M., Debus, J., von Deimling, A., Simon, M., Unterberg, A., Abdollahi, A., Herold-Mende, C. (2019) Identification of KIF11 as a novel target in meningioma. Cancers, 11(4), 545.
[19] Pei, Y. Y., Li, G. C., Ran, J., Wei, F. X. (2017) Kinesin family member 11 contributes to the progression and prognosis of human breast cancer. Oncology Letters, 14(6), 6618-6626.
[20] Wang, Y., Zhang, Z., Huang, L., Sun, L., Li, S., Zhang, T., Ding, X. (2022) Update on the phenotypic and genotypic spectrum of KIF11-related retinopathy. Genes, 13(4), 713.
[21] Zalenski, A. A., Majumder, S., De, K., Venere, M. (2020) An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics. Scientific Reports, 10(1), 13946.
[22] Wang, B., Bao, L., Li, X., Sun, G., Yang, W., Xie, N., Lei, L., Chen, W., Zhang, H., Chen, M., Zhao, X., Wan, X., Yuan, R., Jiang, H. (2025) Identification and validation of the important role of KIF11 in the development and progression of endometrial cancer. Journal of Translational Medicine, 23(1), 48.
[23] Lin, X., Liu, J., Zhang, N., Zhou, D., Liu, Y. (2024) Decoding the immune microenvironment: Unveiling CD8+ T cell-related biomarkers and developing a prognostic signature for personalized glioma treatment. Cancer Cell International, 24(1), 331.
Share and Cite
Zhu, X., Lv, Q. (2026) KIF11 as a Potential Diagnostic and Prognostic Biomarker for Lower-grade Glioma. Journal of Disease and Public Health, 2(2), 7-21.